Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by Solid1on Dec 18, 2021 6:41am
96 Views
Post# 34243033

RE:RE:2022

RE:RE:2022maybe it has something to do with that it is from a prospectus from February 2021 in this period also the results for phase 1 were published. the Q3 is already long gone, but this could also mean that there could be an announcement every day. 

Unique Cannabinoid Purification
The Company currently purifies unique cannabinoids from natural sources. Current activities are small scale and used for research and development activities. The scale up of these activities will require the purchase of unique cannabis biomass containing targeted cannabinoids. The Company is currently working with customers to narrow objectives of unique cannabinoid commercialization. The total project cost is approximately $1,000,000 of which approximately $200,000 has been incurred to date. Remaining project deliverables including required biomass will cost approximately $800,000. Commercial activities for this project are expected to commence in Q3 2021.

DR. Nadir Arber says he wants to finish the study by the end of the year.
But today I found this https://clinicaltrials.gov/ct2/show/NCT04969172
it says study end for phase 2 July 2022... what's going on there ? 
Phase 2 was already completed in Greece in August? 

<< Previous
Bullboard Posts
Next >>